Skip to main content
Premium Trial:

Request an Annual Quote

ValiGene, Kimeragen Merge To Create New Functional Genomics Co., ValiGen

Premium

N

EWTOWN, Pa.--Kimeragen here and ValiGene of Paris announced that they will merge to create ValiGen, a functional genomics company that will combine the genomics platform under development at ValiGene with chimeraplasty, the gene correction technology being developed at Kimeragen. The new company will apply genomics and chimeraplasty technologies to identify and validate novel targets for therapeutic intervention against major diseases, both for commercial partners and for itself. ValiGen will explore the potential for chimeraplast-based gene repair therapeutics to treat human diseases associated with particular mutations and also investigate agricultural applications. The merged company will have approximately 100 employees at operations here and in Paris.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.